Thomas Van Blarcom - Concepedia

Concepedia

Author

Thomas Van Blarcom

Pfizer (United States)ORCID

Also Known As

Mridula Rani, T J Van Blarcom, T. Van Blarcom, THOMAS VAN BLARCOM, Thomas J Van Blarcom, Thomas J. Van Blarcom, Thomas Van Blarcom

134

Publications

1.4K

Citations

19

H-Index

51

Concepts

All Affiliations

Pfizer (United States)Allogene Therapeutics (United States)The University of Texas at Austin Bristol-Myers Squibb (Germany)AIR Worldwide (United States)

TV

About

Thomas Van Blarcom is an author at Pfizer (United States) specializing in medicine, antibody engineering, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	414
2	Engineering	5	5	469
3	Natural Sciences	4	4	348
4	Biochemistry	2	2	57
5	Biomedical Engineering	1	1	105

Thomas Van Blarcom

×

24

Publications

1.4K

Citations

19

H-Index

	Year	Citations
Isolation of engineered, full-length antibodies from libraries expressed in Escherichia coli Yariv Mazor, Thomas Van Blarcom, Robert L. Mabry, Nature Biotechnology EngineeringNatural SciencesBiotechnologySynthetic BiologyMolecular Biology	2007	212
Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma Cesar Sommer, Bijan Boldajipour, Tracy C. Kuo, Molecular Therapy	2019	156
Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity Shih-Hsun Chen, Pawel K. Dominik, Jessica Stanfield, Journal for ImmunoTherapy of Cancer	2021	133
High-Throughput Epitope Binning Assays on Label-Free Array-Based Biosensors Can Yield Exquisite Epitope Discrimination That Facilitates the Selection of Monoclonal Antibodies with Functional Activity Yasmina Abdiche, Adam Miles, Josh Eckman, PLoS ONE Identical EpitopeImmunocytochemical TechniqueEngineeringEpitope Binning AssaysImmunology	2014	105
Synthetic Antibodies Designed on Natural Sequence Landscapes Wenwu Zhai, Jacob Glanville, Markus Fuhrmann, Journal of Molecular Biology Synthetic AntibodiesEngineeringSynthetic BiologyGenetic EngineeringAntibody Engineering	2011	95
Preclinical Development and Evaluation of Allogeneic CAR T Cells Targeting CD70 for the Treatment of Renal Cell Carcinoma Siler H. Panowski, Surabhi Srinivasan, Nguyêñ Duy Tân, Cancer Research	2022	84
Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer Guoyun Zhu, Davide Foletti, Xiaohui Liu, Scientific Reports	2019	70
Precise and Efficient Antibody Epitope Determination through Library Design, Yeast Display and Next-Generation Sequencing Thomas Van Blarcom, Andrea Rossi, Davide Foletti, Journal of Molecular Biology BioinformaticsImmunocytochemical TechniqueLibrary DesignYeast DisplayMedicine	2014	66
E-clonal antibodies: selection of full-length IgG antibodies using bacterial periplasmic display Yariv Mazor, Thomas Van Blarcom, Brent L. Iverson, Nature Protocols Immunocytochemical TechniqueAutoimmune DiseaseMedicinePathogenesisImmunology	2008	51
Direct control of CAR T cells through small molecule-regulated antibodies Spencer Park, Edward Pascua, Kevin C. Lindquist, Nature Communications Adaptive Immune SystemT-regulatory CellImmunologyAntigen ProcessingImmunotherapy	2021	47

Page 1